Amiodarone-Induced Hypothyroidism: Causes and Treatment

Amiodarone-induced hypothyroidism (AIH) is an underactive thyroid caused by the antiarrhythmic drug amiodarone, and it is the more common of the two thyroid problems the drug can trigger. In a large nationwide study with over 27,000 patients followed for an average of about six years, roughly one in nine developed hypothyroidism while on the medication. The condition stems primarily from the enormous iodine load the drug delivers to the body, though the full picture involves several overlapping mechanisms and a strong influence from pre-existing thyroid vulnerability.

Why Amiodarone Overwhelms the Thyroid with Iodine

Amiodarone is about 37 percent iodine by weight, and a standard 200 mg maintenance dose delivers far more iodine than anyone would get through diet. Pharmacokinetic studies show that at steady state, the drug and its main breakdown product (desethylamiodarone) account for only about a third of the total iodine circulating in the blood. The rest exists as a pool of other iodine-containing substances released during the drug’s metabolism, with inorganic iodide alone reaching concentrations at least 40 times above the normal upper limit.¹ That flood of free iodide is what sets the thyroid up for trouble. Making matters worse, amiodarone is extremely fat-soluble, accumulates in tissues over months, and has a half-life that can stretch beyond 100 days. Even after stopping the drug, iodine levels remain elevated for a long time.

The Core Mechanism Behind AIH

A healthy thyroid has a built-in safety valve for iodine overload. When iodide concentrations spike, the gland temporarily shuts down hormone production to protect itself. This protective slowdown, known as the Wolff-Chaikoff effect, is normally a brief pause: within a couple of days the thyroid adapts, downregulates iodide transport, and resumes making hormones as usual. In people who develop AIH, the thyroid fails to make that adaptation. Instead of escaping the temporary shutdown, it stays stuck in the suppressed state, and hormone output drops.²

Why some thyroids can’t escape and others can appears to come down to subtle pre-existing defects in the gland’s hormone-making machinery. People whose thyroids are already slightly compromised, whether by undiagnosed autoimmune inflammation or minor enzymatic quirks, seem far less able to recover from the iodine-driven shutdown.³ The persistent iodine excess from amiodarone simply pushes the gland past a threshold it can’t bounce back from.

Other Ways Amiodarone Disrupts Thyroid Hormones

Beyond flooding the thyroid with iodine, amiodarone also interferes with what happens to thyroid hormones after they leave the gland. Most of the body’s active thyroid hormone (T3) is produced not in the thyroid itself but in peripheral tissues like the liver and kidneys, where an enzyme converts the less active T4 into T3. Amiodarone blocks that enzyme, reducing T3 production in the body’s tissues and raising levels of an inactive form called reverse T3.⁴ This creates a tricky clinical picture: many patients on amiodarone show elevated T4 and depressed T3 on blood tests yet feel perfectly fine and are, for all practical purposes, euthyroid, meaning their overall thyroid function is adequate.⁵ This is one reason interpreting thyroid labs in someone taking amiodarone requires a different reference frame than in the general population.

There is also evidence that amiodarone and desethylamiodarone are directly toxic to thyroid cells. Laboratory studies on human thyroid tissue show that the drug damages thyroid follicles, and the effect is greater in cells that are actively trapping and processing iodide. Blocking iodide processing partially reduced the damage, suggesting both the drug itself and the excess iodide it releases contribute to cell injury.⁶ This direct toxicity may help explain why thyroid dysfunction sometimes persists or worsens even after the drug is stopped, since the accumulated tissue damage takes time to heal, if it fully does.

Who Is Most at Risk

The single strongest risk factor for AIH is pre-existing autoimmune thyroid disease, particularly Hashimoto’s thyroiditis. In one study, five of seven patients with detectable thyroid autoantibodies became hypothyroid within four to nine months of starting amiodarone, and their antibody levels rose during treatment.⁷ A thyroid gland already under immune attack has less functional reserve and is far less equipped to handle the iodine overload. The Endocrine Reviews characterization that Hashimoto’s is a “definite risk factor” for AIH reflects a wide consensus.²

Geography matters, too, in a way that surprises many people. AIH is more common in countries and regions where dietary iodine intake is sufficient or high. In a comparison of patients in West Tuscany (where iodine intake is low) and Worcester, Massachusetts (where iodine intake is adequate), hypothyroidism occurred in about 22 percent of the Worcester patients but only rarely in the Tuscan group, where hyperthyroidism was the bigger problem at nearly 10 percent.⁸ The explanation is that in iodine-sufficient areas, thyroids are already well-saturated and less able to tolerate the additional iodine from amiodarone. In iodine-deficient regions, the gland is primed to use every bit of iodine it can get, and the sudden surplus is more likely to trigger overactivity than underactivity.⁹

Women are generally more susceptible to autoimmune thyroid disease than men, which likely contributes to a higher AIH rate in women, though amiodarone-induced thyroid problems affect both sexes. A large retrospective cohort study found an overall hypothyroidism incidence rate of about 17 per 1,000 person-years among amiodarone users, with the overactivity form (thyrotoxicosis) occurring at roughly 7 per 1,000 person-years.¹⁰ So hypothyroidism is roughly twice as common as the overactive form, at least in populations with adequate iodine intake.

Abnormal Lab Values That Are Not Actually AIH

One of the most common sources of confusion, for patients and clinicians alike, is that amiodarone changes thyroid blood tests in virtually everyone who takes it. Within the first few months of treatment, T4 typically rises, T3 falls, reverse T3 goes up, and TSH may transiently increase before settling back toward normal. These shifts reflect amiodarone’s blockade of peripheral T4-to-T3 conversion and do not mean the patient is hypothyroid.⁴ If TSH remains persistently elevated (typically above 10 mU/L) alongside low free T4 and the patient has symptoms such as fatigue, weight gain, cold intolerance, or mental sluggishness, that is when true AIH is diagnosed. Clinicians following amiodarone patients need to interpret results against amiodarone-specific reference ranges rather than the normal population values, which is part of why routine monitoring before and during treatment is strongly recommended.

Treatment with Levothyroxine

The standard treatment for AIH is levothyroxine (synthetic T4), the same medication used for any other form of hypothyroidism. European Thyroid Association (ETA) guidelines recommend treating all cases of overt AIH with levothyroxine but note that treatment may be deferred in some subclinical cases, particularly in elderly patients, as long as thyroid function is checked frequently to catch progression.¹¹

Dose adjustment follows a different logic than in ordinary hypothyroidism. Because amiodarone is still blocking the conversion of T4 to T3 in peripheral tissues, normalizing TSH can require levothyroxine doses that seem uncomfortably high for patients with underlying heart disease. One early study found a mean dose of 136 micrograms per day was needed to bring T4 levels into the expected range for amiodarone users, and noted that fully suppressing TSH into the normal range would have required even higher doses that clinicians judged too risky.¹² The ETA guidelines explicitly address this by recommending that clinicians target free T4 and free T3 normalization while accepting TSH values in the upper third of the normal range or even slightly above (up to about 10 mU/L) in overt cases, specifically to avoid the cardiac risks of overreplacement.¹¹

Does Amiodarone Need to Be Stopped?

This is often the first question patients ask, and the answer is usually no. Unlike amiodarone-induced thyrotoxicosis, which sometimes requires stopping the drug, AIH is considered straightforward to manage with levothyroxine while continuing amiodarone. The ETA guidelines state that amiodarone withdrawal is not required for AIH, particularly when the drug is considered essential for the patient’s cardiac condition.¹¹ This is reassuring because amiodarone is often the only antiarrhythmic that adequately controls a patient’s arrhythmia. Stopping it solely because of hypothyroidism could trade a manageable thyroid problem for a life-threatening heart rhythm disorder.

If amiodarone is eventually discontinued for other reasons, hypothyroidism often resolves over time as the iodine stores are slowly cleared from the body. Some estimates suggest about 15 to 20 percent of amiodarone-treated patients develop some form of thyroid dysfunction, and in many of those cases the problem reverses once the drug is out of the system.⁹ However, because amiodarone’s tissue half-life is so long, recovery can take many months. Patients with underlying Hashimoto’s thyroiditis may never fully recover thyroid function regardless of whether amiodarone is stopped.

Pregnancy and Fetal Risk

Amiodarone crosses the placenta, and so does the iodine released from its metabolism. The fetal thyroid is particularly vulnerable because it develops the ability to escape from the Wolff-Chaikoff effect only late in pregnancy. Before that point, the iodine overload can suppress fetal thyroid function, causing neonatal hypothyroidism and sometimes goiter.¹³ Follow-up assessments of affected infants have found mild neurodevelopmental abnormalities in some cases, including features reminiscent of nonverbal learning difficulties. Interestingly, some of these abnormalities also appeared in amiodarone-exposed infants who remained euthyroid, raising the possibility that the drug has direct neurotoxic effects independent of the thyroid pathway.

A Canadian study of pregnancies exposed to amiodarone confirmed the range of complications: perinatal hypothyroidism or hyperthyroidism, potential neurologic problems, growth restriction, and fetal bradycardia.¹⁴ While pregnancy and breastfeeding are not absolute contraindications for amiodarone, the consensus is that it should be used only when no safer alternative exists and the mother’s cardiac condition is life-threatening. Neonatal thyroid screening should always be performed when there has been in-utero exposure, and transient hypothyroidism in the newborn typically resolves within weeks to months with appropriate treatment.¹⁵

Children and Infants on Amiodarone

Amiodarone is sometimes used in pediatric patients with complex congenital heart disease or refractory arrhythmias. The risk of thyroid dysfunction applies just as much in children, and the stakes can be higher: hypothyroidism during infancy and early childhood can impair neurodevelopment, growth, and cognitive milestones in ways that are difficult to reverse if treatment is delayed.¹⁶ Case reports and reviews emphasize that early and proper diagnosis of AIH in young patients allows prompt treatment while carefully accounting for the child’s underlying cardiac status.¹⁷ Thyroid function tests should be monitored more vigilantly in pediatric patients than in adults because the consequences of missed hypothyroidism are more severe in a developing brain.

Subclinical Hypothyroidism and How It Feels

Not all AIH is immediately obvious. Some patients develop subclinical hypothyroidism, where TSH is elevated but free thyroid hormone levels remain in the normal range and symptoms are absent or vague. Research on subclinical hypothyroidism in general (not limited to amiodarone-related cases) suggests it is not associated with major cognitive or psychiatric deficits, though sensitive testing can pick up small decrements in memory and executive function.¹⁸ One observation from that research is that neuropsychiatric complaints are more common when patients know they have thyroid disease, regardless of whether their hormone levels are actually abnormal at the time of testing. This nocebo-like effect can complicate the clinical picture and lead to unnecessary dose escalations.

For subclinical AIH specifically, the decision to treat with levothyroxine is not automatic. In younger patients or those with symptoms, treatment makes sense. In elderly patients whose main concern is cardiac stability, watchful waiting with regular blood work is reasonable, since the risks of overreplacement in someone with a fragile heart may outweigh the benefits of normalizing a mildly elevated TSH.

Genetic Susceptibility

Researchers are beginning to identify genetic markers that predict who is likely to develop AIH. A genome-wide association study found two risk-associated regions. One variant, near the FOXE1 gene (a gene already linked to thyroid development and function), showed a strong protective effect when present, with carriers having roughly 60 percent lower odds of AIH. A second variant near the FOXA2 gene showed a more modest association.¹⁹ These findings are still in the early research stage and are not yet used clinically, but they point toward a future where a simple genetic test before starting amiodarone could identify patients at highest risk and guide monitoring or drug selection accordingly.

Dronedarone as an Alternative

Dronedarone was specifically developed as a structural cousin of amiodarone that lacks the iodine atoms responsible for most of amiodarone’s thyroid toxicity. Clinical experience has borne that out: no serious thyroid or pulmonary toxicities have been reported with dronedarone, making it a potential option for patients who need rhythm control but are at high risk for thyroid problems.²⁰ The trade-off is that dronedarone is generally considered less effective than amiodarone for maintaining sinus rhythm, and it carries its own restrictions, including contraindications in patients with heart failure. For many patients with serious or refractory arrhythmias, amiodarone remains the only viable drug, and managing its thyroid side effects is simply part of the bargain.